Compare GITS & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GITS | NVNO |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | South Korea | United States |
| Employees | 5 | 33 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.9M |
| IPO Year | N/A | N/A |
| Metric | GITS | NVNO |
|---|---|---|
| Price | $2.02 | $10.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 937.7K | 12.9K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $140.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.30 |
| 52 Week High | $7.09 | $13.44 |
| Indicator | GITS | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 50.23 |
| Support Level | $1.45 | $9.93 |
| Resistance Level | $2.26 | $11.15 |
| Average True Range (ATR) | 0.18 | 0.73 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 36.27 | 25.98 |
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.